STOCK TITAN
  1. Home
  2. News
  3. ICAD

Icad Inc - ICAD STOCK NEWS

Welcome to our dedicated page for Icad news (Ticker: ICAD), a resource for investors and traders seeking the latest updates and insights on Icad stock.

ICAD Inc. (symbol: ICAD) is a leading force in the realm of medical technology, specializing in advanced image analysis, workflow solutions, and radiation therapies designed for the early detection and treatment of cancers.

Core Business: The company’s main operations focus on providing healthcare professionals with cutting-edge tools to identify pathologies through a comprehensive range of high-performance, upgradeable computer-aided detection (CAD) solutions. These solutions are pivotal in mammography for breast cancer, magnetic resonance imaging (MRI) for breast and prostate cancers, and computed tomography (CT) for colorectal cancer. ICAD’s flagship technology, the Xoft® System, delivers radiation treatment for early-stage breast cancer via intraoperative radiation therapy (IORT) and accelerated partial breast irradiation (APBI). Additionally, the Xoft System is approved for treating non-melanoma skin cancer and endometrial cancer.

Recent Achievements and Partnerships: Recently, ICAD announced the integration of key AI-powered solutions from its ProFound™ Breast Health Suite into GE HealthCare's MyBreastAI Suite, aimed at enhancing breast cancer detection worldwide. This collaboration underscores ICAD's commitment to advancing breast health, improving diagnostic accuracy, and streamlining workflow efficiency for clinicians.

Financial Condition: As of the first quarter of 2024, ICAD reported a total revenue of $5.0 million, marking a 14% increase from the previous year. The company's gross profit stood at $4.1 million, with an operating expense reduction of 18%, showcasing robust financial health and strategic cost management.

Global Reach: ICAD’s influence extends across multiple countries including France, Belgium, Italy, Germany, Switzerland, and others, reflecting its strong international presence and commitment to global healthcare improvement.

Innovative Solutions: ICAD’s ProFound AI technology has demonstrated significant benefits in clinical studies, including improved radiologist sensitivity and specificity, reduced reading times, and decreased unnecessary patient recall rates. The company’s solutions are used by thousands of providers, serving millions of patients, and are available in over 50 countries.

Future Prospects: ICAD continues to innovate with the recent introduction of the ProFound Cloud, powered by Google Cloud, to enhance the accessibility and efficiency of mammography screening data. The company also remains committed to expanding its AI capabilities and improving patient outcomes globally through strategic partnerships and technological advancements.

For more information, visit www.icadmed.com or contact their media and investor relations at pr@icadmed.com and ir@icadmed.com respectively.

News

iCAD Expands Executive Sales Leadership Team as Business Grows

Rhea-AI Summary
iCAD, Inc. (NASDAQ: ICAD) expands its sales leadership with the addition of Peter Graham as Senior Vice President, North American Sales, and a role change for Bill Keyes to Senior Vice President, Global Sales Operations. The company aims to drive growth, increase revenue, and deliver results by introducing new solutions under the ProFound Breast Health Suite portfolio and launching programs with new partners.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.36%
Tags
management
-
News

iCAD’s AI-powered solutions to Help Accelerate Breast Cancer Detection in New Collaboration with GE Healthcare

Rhea-AI Summary
iCAD, Inc. (ICAD) announces integration of key AI applications from its ProFound Breast Health Suite with GE HealthCare’s new MyBreastAI Suite, aimed at streamlining workflow and supporting clinicians in delivering personalized breast care. The AI solutions aim to enhance breast cancer detection and diagnosis while optimizing workflow efficiency to elevate patient care outcomes globally.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.6%
Tags
AI
-
News

iCAD’s ProFound AI Can Predict 1-2 Year Risk for Breast Cancer and Reveal Insights for Heart Disease

Rhea-AI Summary
iCAD, Inc. (NASDAQ: ICAD) presents new research at RSNA annual meeting showcasing the ProFound Breast Health Suite's ability to predict a woman’s one to two-year risk for breast cancer and assess calcium deposits in the breast arteries as a proxy for hidden cardiovascular disease. The AI-powered solution improves cancer detection rates, reduces false positive results, and accurately evaluates a woman’s breast density and cancer risk.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.24%
Tags
AI
News

iCAD and CancerIQ Announce Partnership to Integrate AI-Enabled Technology With Best-in-Class Risk Assessment and Care Management Platform Offering A Comprehensive Breast Health Care Solution  

Rhea-AI Summary
iCAD, Inc. (NASDAQ: ICAD) and CancerIQ announced a partnership to provide a comprehensive breast health care solution, combining iCAD's ProFound Breast Health Suite with CancerIQ's precision cancer prevention platform. The partnership aims to inform physicians and patients of cancer risk, identify breast cancer at earlier stages, and increase patient adherence to personalized care plans. By integrating AI-informed 1- or 2-year risk with lifetime risk, the solutions offer a 2.4x more accurate prediction of breast cancer risk. The partnership announcement coincides with iCAD's appearance at the Radiological Society of North America (RSNA) annual meeting in Chicago, unveiling new research using AI in breast cancer risk detection and heart disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.72%
Tags
partnership AI
-
News

iCAD to Participate in the 14th Annual Craig-Hallum Alpha Select Conference

Rhea-AI Summary
iCAD, Inc. (NASDAQ: ICAD) Announces Participation at the 14th Annual Craig-Hallum Alpha Select Conference. The company's President and CEO, Dana Brown, and CFO, Eric Lonnqvist, will be attending the conference to host one-on-one meetings with investors and attendees. The event will take place at the Sheraton New York Times Square in New York City, offering an opportunity for investors to connect with the company's management.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.99%
Tags
conferences
-
News

iCAD Reports Financial Results for Third Quarter Ended September 30, 2023

Rhea-AI Summary
iCAD, Inc. (NASDAQ: ICAD) reports Q3 financial results, re-introduces Annual Recurring Revenue (ARR) metrics, and completes sale of Xoft, focusing on AI-powered breast health solutions. The company plans to host a conference call and webcast today at 4:30 PM ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.99%
Tags
earnings
News

iCAD to Report Third Quarter 2023 Financial Results on November 13, 2023

Rhea-AI Summary
iCAD, Inc. will release its financial results for the third quarter ended September 30, 2023, after the market close. The company is a global leader in AI-powered breast health solutions. A conference call will be held on November 13, 2023, at 4:30 PM Eastern Time.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.75%
Tags
conferences earnings
-
News

iCAD, Inc. Announces Sale of Xoft, its Brachytherapy Business Line, to Elekta

Rhea-AI Summary
Elekta acquires Xoft, a subsidiary of iCAD, Inc., for $5.5 million to expand access to electronic brachytherapy technology for cancer treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5%
Tags
none
-
News

Health Canada Grants Device License for iCAD's ProFound Risk 2.0, Revolutionizing Breast Cancer Risk Via a 1-2 Year Assessment

Rhea-AI Summary
iCAD, Inc. (NASDAQ: ICAD) - Health Canada issued a device license for ProFound Risk version 2.0, iCAD's personalized 1-2 year breast cancer risk assessment solution. The technology uses AI to provide personalized, accurate, and efficient risk estimations for each woman, offering a more personalized and holistic approach to breast cancer detection and risk assessment. Clinical evidence demonstrates its unique ability to more accurately predict short-term cancer risk compared to traditional risk models. The device license represents a significant milestone in iCAD's mission to improve breast cancer risk assessment and patient care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.86%
Tags
none
News

iCAD Reports Financial Results for Second Quarter Ended June 30, 2023 

Rhea-AI Summary
iCAD, Inc. reports financial and operating results for Q2 2023. The company signs a 20-year worldwide development and commercialization agreement with Google Health. They also sign a strategic multi-year commercial agreement with Radiology Partners. iCAD secures its largest subscription deal to-date with a prestigious academic medical center. The company aims to achieve profitability by the end of 2024 through cost reduction measures.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.2%
Tags
earnings

FAQ

What is the current stock price of Icad (ICAD)?

The current stock price of Icad (ICAD) is $1.83 as of December 20, 2024.

What is the market cap of Icad (ICAD)?

The market cap of Icad (ICAD) is approximately 46.7M.

What does ICAD Inc. specialize in?

ICAD Inc. specializes in advanced image analysis, workflow solutions, and radiation therapies for the early detection and treatment of cancers.

What are ICAD's core products?

ICAD’s core products include CAD solutions for mammography, MRI for breast and prostate cancers, and CT for colorectal cancer. The Xoft System is another key product, offering radiation treatment for early-stage breast, non-melanoma skin, and endometrial cancers.

What recent partnerships has ICAD announced?

ICAD recently announced a partnership with GE HealthCare to integrate key AI-powered solutions from its ProFound Breast Health Suite into GE's MyBreastAI Suite, enhancing breast cancer detection and workflow efficiency.

How is ICAD performing financially?

As of Q1 2024, ICAD reported $5.0 million in total revenue, a 14% increase from the previous year. The gross profit was $4.1 million with an 18% reduction in operating expenses.

Where does ICAD operate globally?

ICAD operates in countries including France, Belgium, Italy, Germany, Switzerland, and others, indicating a strong international presence.

What is the ProFound Cloud?

ProFound Cloud is an innovative solution powered by Google Cloud, designed to enhance the accessibility and efficiency of mammography screening data for radiologists.

What are the benefits of ICAD’s ProFound AI technology?

Clinical studies show that ICAD’s ProFound AI improves reading sensitivity and specificity, reduces reading times, and decreases unnecessary patient recall rates.

How many patients and providers use ICAD's solutions?

ICAD’s solutions are used by thousands of providers, serving millions of patients across over 50 countries.

What is the Xoft System?

The Xoft System is ICAD’s radiation treatment solution for early-stage breast cancer, non-melanoma skin cancer, and endometrial cancer. It offers treatments through IORT and APBI.

How can I contact ICAD for more information?

For more information, visit www.icadmed.com or contact ICAD via pr@icadmed.com for media inquiries and ir@icadmed.com for investor inquiries.

Stock ICAD logo
Icad Inc

Nasdaq:ICAD

ICAD Rankings

#4910 Ranked by Market Cap
N/A Ranked by Dividends

ICAD Stock Data

46.65M
25.05M
5.63%
27.16%
0.95%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
NASHUA